Latest EVLO reports update at 2023-11-09: 2023-Q3 ∙ 2022-Q4 ∙ 2022-Q3

Evelo Biosciences EVLO

$ 0.32 -14.46%

Evelo Biosciences Balance Sheet 2011-2024 | EVLO

Annual Balance Sheet Evelo Biosciences

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-2.07 M	-19.9 M	-37.1 M	-58.2 M	-26 M	-28.3 M	-5.6 M	-	-	-	-	-
Long Term Debt	43.6 M	46.6 M	30 M	19.6 M	12.3 M	9.97 M	9.93 M	-	-	-	-	-
Long Term Debt Current	2.26 M	1.95 M	1.67 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	40.3 M	21 M	13.7 M	10.5 M	10.8 M	-	-	-	-	-
Total Current Liabilities	12.4 M	17.4 M	19.8 M	9.74 M	9.24 M	-	-	-	-	-	-	-
Total Liabilities	69.4 M	79.2 M	60.2 M	30.7 M	22.9 M	14.4 M	13 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-529 M	-415 M	-293 M	-199 M	-113 M	-56.4 M	-28.3 M	-	-	-	-	-
Total Assets	64.4 M	87.9 M	90.6 M	90.9 M	160 M	43.8 M	18.6 M	-	-	-	-	-
Cash and Cash Equivalents	47.9 M	68.4 M	68.9 M	77.8 M	93.1 M	39.7 M	15.8 M	-	-	-	-	-
Book Value	-4.99 M	8.67 M	30.5 M	60.2 M	137 M	29.4 M	5.53 M	-	-	-	-	-
Total Shareholders Equity	-4.99 M	8.67 M	30.5 M	60.2 M	137 M	-54.7 M	-28.3 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Evelo Biosciences

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	43.6 M	36.6 M	40.7 M	44.8 M	46.6 M	46.5 M	46.5 M	29.3 M	30 M	30 M	30 M	30 M	19.6 M	19.6 M	19.6 M	19.6 M	12.3 M	12.3 M	12.3 M	12.3 M	9.97 M	9.97 M	9.97 M	9.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	47.3 M	66.9 M	69.4 M	69.4 M	77 M	76.3 M	75.6 M	79.2 M	83.4 M	83 M	65.2 M	60.2 M	60.2 M	60.2 M	60.2 M	30.7 M	30.7 M	30.7 M	30.7 M	22.9 M	22.9 M	22.9 M	22.9 M	14.8 M	14.8 M	14.8 M	14.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-588 M	-576 M	-555 M	-529 M	-506 M	-475 M	-445 M	-415 M	-386 M	-352 M	-321 M	-293 M	-293 M	-293 M	-293 M	-199 M	-199 M	-199 M	-199 M	-113 M	-113 M	-113 M	-113 M	-56.4 M	-56.4 M	-56.4 M	-56.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	20.6 M	20.8 M	42 M	64.4 M	86.3 M	112 M	58.8 M	87.9 M	116 M	145 M	153 M	90.6 M	90.6 M	90.6 M	90.6 M	90.9 M	90.9 M	90.9 M	90.9 M	160 M	160 M	160 M	160 M	43.8 M	43.8 M	43.8 M	43.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	17.3 M	7.62 M	27.5 M	47.9 M	69.1 M	92 M	39.6 M	68.4 M	95.9 M	125 M	125 M	68.9 M	68.9 M	68.9 M	68.9 M	77.8 M	77.8 M	77.8 M	77.8 M	93.1 M	93.1 M	93.1 M	93.1 M	38.2 M	38.2 M	38.2 M	38.2 M	15.8 M	-	-	-	3.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-26.7 M	-46.1 M	-27.4 M	-4.99 M	9.33 M	35.6 M	-16.8 M	8.67 M	33.1 M	62.1 M	87.8 M	30.5 M	30.5 M	30.5 M	30.5 M	60.2 M	60.2 M	60.2 M	60.2 M	137 M	137 M	137 M	137 M	29 M	29 M	29 M	29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-26.7 M	-46.1 M	-27.4 M	-4.99 M	9.33 M	35.6 M	-16.8 M	8.67 M	33.1 M	62.1 M	87.8 M	30.5 M	30.5 M	30.5 M	30.5 M	60.2 M	60.2 M	60.2 M	60.2 M	137 M	137 M	137 M	137 M	-54.7 M	-54.7 M	-54.7 M	-54.7 M	-28.3 M	-	-	-	-4.47 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency